Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Galmed Pharmaceuticals

NASDAQ GLMD
$0.40 0.0000 0.0000%
Today share price
Israel
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 22 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

2.01M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-927.45K
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.26
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
5.05M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-12.46 %

Upcoming events Galmed Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Galmed Pharmaceuticals

Stock analysis Galmed Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.30 16.17
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
0.14 4.32
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
0.12 8.89
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.39 0.64
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-48.56 4.05

Price change Galmed Pharmaceuticals per year

2.15$ 5.59$
Min Max

Summary analysis Galmed Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Galmed Pharmaceuticals

Revenue and net income Galmed Pharmaceuticals

All parameters

Stock news Galmed Pharmaceuticals

All news
4 January 2023 в 21:40

Galmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol Study

4 January 2023 в 21:35

Galmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol Study

18 May 2022 в 14:31

Galmed Pharmaceuticals downgraded to market perform from outperform at Raymond James

3 May 2022 в 22:00

Galmed Pharmaceuticals Shares Down 16%

3 May 2022 в 21:55

Galmed Pharmaceuticals Shares Down 16%

10 January 2022 в 15:55

Galmed Pharmaceuticals Sees Positive Results for Bowel-Disease Drug

10 January 2022 в 15:55

Galmed Pharmaceuticals Sees Positive Results for Bowel-Disease Drug

About company Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Address:
16 Tiomkin Street, Tel Aviv, Israel, 6578317
Company name: Galmed Pharmaceuticals
Issuer ticker: GLMD
ISIN: IL0011313900
Country: Israel
Exchange: NASDAQ
Currency: $
IPO date: 2014-03-13
Sector: Healthcare
Industry: Biotechnology
Site: https://www.galmedpharma.com

On which stock exchange are Galmed Pharmaceuticals (GLMD) stocks traded?

Galmed Pharmaceuticals (GLMD) stocks are traded on NASDAQ.

What is the ticker of Galmed Pharmaceuticals stocks (GLMD)?

The stock ticker of Galmed Pharmaceuticals’s stocks or in other words, the code is GLMD. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Galmed Pharmaceuticals (GLMD) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Galmed Pharmaceuticals (GLMD) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Galmed Pharmaceuticals (GLMD) stocks traded?

Galmed Pharmaceuticals (GLMD) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Galmed Pharmaceuticals (GLMD) stocks today?

The current price of Galmed Pharmaceuticals stocks on 13.05.2024 is 0.3983 dollars. per share.

What is the dynamics of Galmed Pharmaceuticals (GLMD) stocks from the beginning of the year?

Galmed Pharmaceuticals (GLMD) quotes have increased by -9.42% from the beginning of the year up to 0.3983 dollars. per 1 stocks.

How much did Galmed Pharmaceuticals (GLMD) stocks increase in мае 2024?

This month Galmed Pharmaceuticals (GLMD) quotes have increased by 2.89% to 0.3983 dollars. per share.

How much are Galmed Pharmaceuticals (GLMD) stocks worth?

Today, on October, 13.05.2024 Galmed Pharmaceuticals’s (GLMD) stocks cost 0.3983 dollars..

What is the market capitalization of Galmed Pharmaceuticals (GLMD)?

Capitalization is the market value of Galmed Pharmaceuticals (GLMD) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 13.05.2024, the market capitalization of Galmed Pharmaceuticals (GLMD) is estimated at about 2009553 dollars.